摘要
Abstract
Objective To study the curative effect of neoadjuvant chemotherapy with capecitabine as a benchmark for treating advanced gastric cancer by performing a meta-analysis of the published studies, then provide statistical evidence for the clinical treatment of advanced gastric cancer.Methods The database of Pubmed, CBMdisc, Embase and Cochrane aided with manual retrieval and other retrievals were searched to screen neoadjuvant chemotherapy containing capecitabine in the treatment of advanced gastric cancer in randomized controlled trials (RCT). The RevMan5.2 software was used for meta-analysis after extracting the useful data.Results Eight randomized controlled trials involved a total of 699 patients with advanced gastric cancer were studied. Of the 8 trials, 7 were published by Chinese, 1 were published by English. Of the 699 patients, 351 were treated by neoadjuvant chemotherapy containing capecitabine, 348 were treated by neoadjuvant chemotherapy excluding capecitabine or without treating by neoadjuvant chemotherapy. According to the meta-analysis of the available information, there were statistical differences in 1-year survival rate, radical operation resection rate (RO), total operation rate (R1) (P<0.05). TheOR rate and 95% CI were 2.97 (1.79-4.91) for 1-year survival rate, 2.94 (2.03-4.26) for RO and 3.54 (2.31-5.43) for R1.Conclusion Compared with neoadjuvant chemotherapy excluding capecitabine or patients without neoadjuvant chemotherapy, neoadjuvant chemotherapy containing capecitabine can improve the 1-year survival rate, radical operation resection rate and total operation rate in patients with advanced gastric cancer.关键词
卡培他滨/新辅助化疗/进展期胃癌/Meta分析Key words
capecitabine/neoadjuvant chemotherapy/advanced gastric cancer/meta-analysis分类
医药卫生
